Przejdź do zawartości
Merck

480789

Sigma-Aldrich

Bismuth(III) subsalicylate

99.9% trace metals basis

Synonim(y):

Bismuth oxysalicylate, Bismuth subsalicylate, Bismuth(III) salicylate basic

Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych


About This Item

Wzór liniowy:
HOC6H4COOBiO
Numer CAS:
Masa cząsteczkowa:
362.09
Numer WE:
Numer MDL:
Kod UNSPSC:
12161600
Identyfikator substancji w PubChem:
NACRES:
NA.22

Poziom jakości

Próba

99.9% trace metals basis

przydatność reakcji

core: bismuth
reagent type: catalyst

mp

>350 °C (lit.)

ciąg SMILES

O[Bi]1OC(=O)c2ccccc2O1

InChI

1S/C7H6O3.Bi.H2O/c8-6-4-2-1-3-5(6)7(9)10;;/h1-4,8H,(H,9,10);;1H2/q;+3;/p-3

Klucz InChI

ZREIPSZUJIFJNP-UHFFFAOYSA-K

Opis ogólny

Bismuth(III) subsalicylate (BSS) is mainly used in bismuth-based medicines for treating gastrointestinal disorders and diarrhea.

Zastosowanie

  • Use of ferric chloride to identify salicylate-containing poisons.: This study explores the use of ferric chloride to detect salicylate compounds, including Bismuth subsalicylate, highlighting its significance in toxicological screenings and emergency treatments. (Hoffman RJ et al., 2002).
  • Effect of pepper and bismuth subsalicylate on gastric pain and surface hydrophobicity in the rat.: Investigates the effects of Bismuth subsalicylate on gastric pain and stomach lining properties, providing insights into its gastroprotective mechanisms. (Lichtenberger LM et al., 1998).
  • The coccoid forms of Helicobacter pylori. Criteria for their viability.: Examines the effectiveness of Bismuth subsalicylate in targeting different morphological forms of Helicobacter pylori, contributing to its role in eradication therapies. (Bode G et al., 1993).
  • Bismuth therapy in gastrointestinal diseases.: A comprehensive review of the therapeutic applications of Bismuth subsalicylate in treating various gastrointestinal disorders, underscoring its pharmacological benefits and safety profile. (Gorbach SL, 1990).
This page may contain text that has been machine translated.

Kod klasy składowania

11 - Combustible Solids

Klasa zagrożenia wodnego (WGK)

WGK 3

Temperatura zapłonu (°F)

Not applicable

Temperatura zapłonu (°C)

Not applicable

Środki ochrony indywidualnej

Eyeshields, Gloves, type N95 (US)


Wybierz jedną z najnowszych wersji:

Certyfikaty analizy (CoA)

Lot/Batch Number

Nie widzisz odpowiedniej wersji?

Jeśli potrzebujesz konkretnej wersji, możesz wyszukać konkretny certyfikat według numeru partii lub serii.

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

Klienci oglądali również te produkty

D W Bierer
Reviews of infectious diseases, 12 Suppl 1, S3-S8 (1990-01-01)
Pepto-Bismol, which contains bismuth subsalicylate (BSS) as the active ingredient, has been marketed in the United States for more than 80 years. In the gastrointestinal tract, BSS is converted to salicylic acid and insoluble bismuth salts. The salicylate portion of
M D Manhart
Reviews of infectious diseases, 12 Suppl 1, S11-S15 (1990-01-01)
This report demonstrates that bismuth subsalicylate (BSS) effectively inhibits growth of a number of bacterial strains known to cause diarrhea, including Escherichia coli, Salmonella, Shigella, and Campylobacter. Other bismuth salts and sodium salicylate, a hydrolysis product of BSS in the
Copolymerizations of e-Caprolactone and Glycolide A Comparison of Tin (II) Octanoate and Bismuth (III) Subsalicylate as Initiators.
Kricheldorf HR and Rost S.
Biomolecules, 6(3), 1345-1352 (2005)
Abdurrahman Kadayifci et al.
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 23(1), 8-13 (2012-04-17)
Helicobacter pylori eradication rates with standard triple regimens are worsening, and alternative treatments are urgently needed in some populations. The present study aimed to compare the efficacy of bismuth-based quadruple and concomitant regimens. Consecutive Helicobacter pylori-positive patients with non-ulcer dyspepsia
David J McGee et al.
Antimicrobial agents and chemotherapy, 55(6), 2897-2904 (2011-04-06)
The human gastric pathogen Helicobacter pylori steals host cholesterol, modifies it by glycosylation, and incorporates the glycosylated cholesterol onto its surface via a cholesterol glucosyltransferase, encoded by cgt. The impact of cholesterol on H. pylori antimicrobial resistance is unknown. H.

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej